Although GH deficiency is associated with a higher risk of MASLD, and GH replacement therapy may have potential benefits [5,6,30,31], the direct impact of GH and IGF-1 on hepatic lipid metabolism remains unclear. This evidence concerns the gene IGF1 and metabolic dysfunction-associated steatotic liver disease.